| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Telik, Inc. |
| 750 Gateway Boulevard, South San Francisco, CA 94080 * (650) 244-9303 |
| Business Description | The company is a biopharmaceutical company working to discover, develop and commercialize drugs to treat serious diseases for which there is significant demand for new therapies. |
| Offering Information Company has | |||
| Trading As | TELK (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 3/31/00 |
| Domestic Shares Offered | 5,000,000 | Offer Date | 8/10/00 |
| Foreign Shares Offered | 0 | Filing Range | $9.00 - $11.00 |
| Company Shares | 5,000,000 | Offer Price | $7.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.490 |
| Gross Proceeds | $35,000,000 | Selling | $0.270 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 21,070,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Warburg Dillon Read LLC | Lead Manager | (203) 719-3000 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| Fidelity Capital Markets | Co-manager | |
| Legg Mason Wood Walker, Inc. | Co-manager | (410) 539-4038 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 1.652 | 3.194 | 4.237 | - | - |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | - | - | -8.618 | -6.579 | -7.064 | - | - |
| E.P.S | - | - | -3.950 | -3.000 | -3.210 | - | - |
| Revenue Growth (%) | - | - | 93.34 | 32.655 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.94 | - | - | ||||
| Cash Flow - Inv. | 6.26 | - | - | ||||
| Cash Flow - Fin. | -0.56 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 9.17 | Current Assets | 7.89 | Current Ratio | 1.99 |
| Total Liab. | 4.04 | Current Liab. | 3.96 | Debt Ratio | 44.06% |
| Total Equity | 5.13 | Working Cap. | 3.94 | Debt to Equity Ratio | 0.79 |
| Cash | 1.95 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Sullivan & Cromwell |
| Registrar/Transfer Agent | Norwest Bank of Minnesota |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Sanwa Kagaku Kenkyusho Co., Ltd. | 15.20 | |
| Atlas V Management Partners, L.P. | 12.60 | |
| International BM Biomedicine Holdings AG | 9.20 | |
| Advent International Corporation | 7.50 | |
| Weiss, Peck & Greer Venture Partners II, L.P. | 6.80 | |
| Oxford Biosciences Management Corp. | 5.40 | |
| Delphi Management Partners II, L.P. | 5.40 | |
| Alpha Venture Partners III | 4.80 | |
| Note: represents ownership of 5% or more prior to the offering. | ||